HALO®

BIOPHARMACEUTICALS

HALO 160 Å PCS C18 vs. C18 Peptide Panel

352



TEST CONDITIONS:

Column: HALO 160 Å PCS C18 , 2.7 µm, 2.1 x 100 mm
Part Number: 92812-617
Comparison Column: SPP 160 Å C18, 2.7 µm, 2.1 x 100 mm
Mobile Phase A: Water/ 0.1% Formic Acid
Mobile Phase B: Acetonitrile/ 0.1% Formic Acid

Gradient:	Time	%B
	0.0	2
	10.0	35

Flow Rate: 0.3 mL/min
Temperature: 30 °C
Injection Volume: 1.0 µL
Wavelength: PDA, 280 nm
Flow Cell: 1 µL
Data Rate: 100 Hz
Response Time: 0.025 sec.
LC System: Shimadzu Nexera X2

PEAK IDENTITIES

1. Uracil
2. S1Y Sequence: RGAGGLYLGK-NH2
3. S2Y Sequence: Ac-RGGGGLYLGK-NH2
4. S3Y Sequence: Ac-RGAGGLYLGK-NH2
5. S4Y2 Sequence: Ac-RGVGYLGLGK-NH2
6. S5Y Sequence: Ac-RGVVGLYLGK-NH2
7. Insulin Chain B Oxidized

A synthetic peptide panel is screened on 160 Å PCS C18 compared to a C18 stationary phase. While using low ionic strength mobile phases such as formic acid the positively charged surface stationary phase shows narrower peak widths and improved peak asymmetry when compared to a traditional C18 stationary phase without endcapping.

advancedmaterialstechnology

Made in the USA | halocolumns.com

INNOVATION YOU CAN TRUST,
PERFORMANCE YOU CAN RELY ON